Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules ("CTAP101 Capsules") in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The newly initiated trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of CTAP101 Capsules as a new treatment for SHPT in the targeted population.  The endpoints of both studies, which will be conducted in parallel, include vitamin D status, adverse events, physical and clinical laboratory assessments, and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).

"Secondary hyperparathyroidism develops in CKD patients due to vitamin D insufficiency or declining kidney function," explained Joel Z. Melnick, M.D., Cytochroma's Vice President, Clinical Research and Development. "Most CKD patients have insufficient stores of vitamin D due to the abnormal upregulation of CYP24, an enzyme which specifically destroys vitamin D and its metabolites. Many recent studies in CKD patients have demonstrated that over-the-counter and prescription vitamin D supplements cannot reliably raise blood vitamin D prohormone levels or effectively treat SHPT. In contrast, our phase 2b trial has demonstrated that CTAP101 Capsules effectively and safely treat both SHPT and the underlying vitamin D insufficiency."

The ongoing phase 3 trial will involve 210 patients recruited from approximately 30 sites in the United States (US). These patients will be stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either CTAP101 Capsules or matching placebo. Dosing with CTAP101 Capsules will start at 30 mcg/day and be titrated, as necessary, to achieve the desired drug concentration in the blood and the targeted reduction in plasma PTH.

"CTAP101 Capsules are being developed as a much needed and safer alternative to currently used activated vitamin D hormones," commented Dr. David Bushinsky, Chief of Nephrology at the University of Rochester. "Activated vitamin D hormone therapy is problematic in CKD patients with secondary hyperparathyroidism arising primarily from vitamin D insufficiency since it further stimulates catabolism of the available vitamin D stores and is often associated with hypercalcemia, a side effect linked to vascular calcification."

The phase 3 program will be funded, in part, by committed financings of nearly $CDN 32 million of which the first two stages closed earlier this year. The lead investors in the financings were Covington Fund II (Toronto) and Business Development Bank of Canada (Montreal). Participating investors included the Bombardier Trust (Canada) Funds (Montreal), Caisse de dépôt et placement du Québec (Québec), Comerica Bank (Toronto), GrowthWorks (Toronto), MaRS Investment Accelerator Fund (Toronto), Partners Group (Zug), Roseway Capital Sarl (Luxembourg) and VentureLink Innovation Fund (Toronto).

"Covington is delighted to support the phase 3 development of CTAP101 Capsules," stated Ms. Lily Lam, VP Investments, Covington and a director of Cytochroma. "Speaking on behalf of all participants in these financings, we view CTAP101 Capsules as a well-advanced and low risk product candidate with high commercial prospects under rapid development by an experienced management team."

The two identical pivotal Phase 3 trials are covered by a Special Protocol Assessment granted by the US Food and Drug Administration (FDA) on August 30, 2012.

Source:

Cytochroma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Increased docosahexaenoic acid intake may lower risk for Alzheimer’s and dementia